Clamart, France — June 1, 2026 — MicroPort CardioFlow Medtech Corporation (02160.HK, “MicroPort CardioFlow”) today announced the commercial launch of LBBOT Solution¹ in Europe and Australia, an innovative portable real-time ECG solution designed to support physicians in clinical practice through continuous 12-lead electrocardiogram (“ECG”) monitoring, automated ventricular activation timing measurements, a clinical assessment tool that supports procedural decision-making.

LBBOT Solution¹ provides continuous 12-lead ECG display with real-time V6 RWPT and V6–V1 interval measurements to support pacing procedure optimization. Designed to integrate seamlessly into existing clinical workflows, the solution combines portability, intuitive operation, and advanced real-time visualization capabilities.

LBBOT Solution¹ consists of the MicroPort CardioFlow Smart ECG device, Hookup Smart Software, and the RC115 cable. Its compact architecture and Bluetooth^®-enabled connectivity allow efficient access to critical pacing information across a wide range of clinical environments, including electrophysiology laboratories, operating rooms, and outpatient centers.

By automating standardized measurements and delivering continuous beat-to-beat insights in real time, LBBOT Solution¹ helps physicians improve procedural consistency and supports confident clinical decision-making.

“LBBOT Solution¹ reflects our commitment to advancing physiological pacing procedures through smarter, data-driven technologies,” said Amel Amblard, Vice-President Clinical Affairs - MicroPort CardioFlow. “By combining automated measurements, continuous ECG visualization, and intuitive workflow integration, LBBOT Solution¹ delivers reliable real-time insights that support procedural efficiency, consistency, and physician confidence.”

LBBOT Solution¹ is now commercially available in Europe and Australia following applicable regulatory clearances.

Concomitantly, the LBBOT clinical study, designed as an acute multicenter evaluation of implantation procedures, assessed as its primary objective the capability of the Smart ECG system to monitor LBB success criteria by evaluating the proportion of investigators providing an overall favorable assessment of the system’s use to achieve Left Bundle Branch Area Pacing (LBBAP). Secondary objectives included the assessment of device handling compared with standard electrophysiology systems. A total of 55 patients were enrolled across six investigational sites in France and Spain, with patient enrollment completed in April 2026.

About MicroPort CardioFlow:

MicroPort CardioFlow is a global leader in innovation within the field of structural heart intervention and cardiac rhythm management. While continuously solidifying its absolute leading position in China's TAVI market and its innovative pipeline advantage across all valvular disease treatments, the company is deeply integrating MicroPort CRM's over 60 years of professional expertise, its 12 core product pipelines, and its global portfolio of more than 40 marketed products covering pacemakers, ICDs, and other areas. It is fully committed to building a world-leading integrated platform spanning “structural heart intervention, rhythm management, and heart failure care," thereby constructing a comprehensive device-based management solution for heart failure that covers all etiologies, all stages, and the entire care cycle. By providing physicians and patients with innovative, full-cycle heart failure health management services, the company is dedicated to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

More information is available at: https://en.cardioflowmedtech.com/  

Reference:

1. The name LBBOT Solution derives from the Clinical Investigation “Left Bundle Branch Area Pacing (LBBAP) Monitoring Assistant: Evaluation of a Portable ECG Solution.” The LBBOT Solution is composed of the Smart ECG device, Hookup Smart Software, and the RC115 cable.